pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Faster Aspart
Phase 1 · small molecule · Diabetes Mellitus, Type 1
Faster Aspart for Diabetes Mellitus, Type 1 is a Phase 1 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Internal code NN1218-4316
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Diabetes Mellitus, Type 1
- Status
- completed
- Trials
- 1